Old and New Drugs in Therapeutic Approach for Trigeminal Neuralgia

A new focus on the actual therapeutic drugs its pretend with this Mini Review acting on trigeminal neuralgia (TN) evaluating their efficacy as also side effects. Besides the common search sources, reviews on trials meta-analyses belong to drug therapy for Trigeminal Neuralgia (TN); other important review manuscript were added from its publication lists and case reports to take this review.Interesting, that carbamazepine, among of the TN´s drugs is the exception that had been adequately studied. Related to applied TN´s both carbamazepine and oxcarbazepine at the moment continue to be the basic option for therapy for common TN. When the patients that not belonging to the first line or having toxic side effect from carbamazepine, lamotrigine and baclofen can be considered as second-line drugs. It was observed that to improve drug tolerance it is possible to the therapy of associations using carbamazepine, gabapentin, baclofen, tizanidine, ropivacaine, and pimozide and where were obtained satisfactory outcomes and enhanced of acceptance therapy. Intravenous lidocaine and ketamine is possible to use to treat acute conditions and botulinum toxin-A can be used in refractory situations. Unfortunately, proparacaine, dextromethorphan and tocainide were considered unsuitable for therapy of TN. The use of anticonvulsants is fortunate controlling trigeminal neuralgia; however, there have been a lack of research with enough of proof, making it antagonizing to compare or in some cases combine their outcomes statistically form a useful way. Novel research on other drugs, association therapies, newer formulations and products, such as vixotrigine, desvenlafina and Cannabis are awaited. Some reports concluded that the possible benefit of Cannabis-based medicine in confirmed neuropathic pain outweighs the possible risks. In addition, there is conclusive efficacy evidence on use of medical drugs in the treatment of TN.